ProKidney Corp. (PROK) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. ProKidney Corp. is a late-clinical-stage biotechnology company developing rilparencel, an autologous cell therapy for advanced chronic kidney disease (CKD) and type 2 diabetes. The company operates as a single segment and is currently conducting its Phase 3 PROACT 1 clinical trial. The company completed a domestication from the Cayman Islands to Delaware effective July 1, 2025, and subsequent restructuring.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $226 | $230 |
| Net Loss (Class A Stockholders) | $(20,037) | $(16,734) |
| Net Loss (Total) | $(42,621) | $(37,952) |
| Operating Expenses | $45,159 | $41,618 |
| Research & Development | $33,842 | $27,263 |
| General & Administrative | $11,317 | $14,355 |
| Cash & Cash Equivalents | $101,895 | $97,805 |
| Marketable Securities | $123,049 | $161,480 |
| Total Assets | $292,784 | $335,574 |
| Net Cash Used in Operating Activities | $(41,684) | $(29,592) |
Note: Revenue consists entirely of lease income from subletting facility space. The company has no product sales.
Material Changes vs. Prior Period
- Increased R&D Spend: Research and development expenses rose by $6.6 million (24%) to $33.8 million, driven primarily by a $6.5 million increase in clinical study costs and manufacturing materials for the ongoing Phase 3 PROACT 1 trial.
- Decreased G&A: General and administrative expenses fell by $3.0 million (21%) to $11.3 million, attributed to reduced equity-based compensation ($1.2M), lower professional fees ($1.4M), and reduced severance costs.
- Lower Interest Income: Interest income decreased by $1.7 million to $2.3 million due to lower investment balances and interest rates compared to the prior year.
- Balance Sheet Shift: Total assets decreased by $42.8 million, primarily due to a reduction in marketable securities ($38.4M decrease) and cash equivalents ($6.6M decrease), offset by an increase in fixed assets related to facility expansion.
Outlook, Risks, and Management Commentary
- Clinical Trial Timeline: Management anticipates a topline data readout for the surrogate endpoint (eGFR slope) of the PROACT 1 trial in Q2 2027, with confirmatory endpoint data expected in the second half of 2029.
- Liquidity: As of March 31, 2026, the company held approximately $225 million in cash, cash equivalents, and marketable securities. Management estimates these resources will fund operations into mid-2027.
- Capital Resources: The company has an "at-the-market" sales agreement (2025 Sales Agreement) with Jefferies LLC for up to $200 million in aggregate offering price. Approximately $175 million remains available under this agreement.
- Risks: The company faces significant risks regarding the success of clinical trials, regulatory approval, and the need for substantial additional funding. There is no assurance that rilparencel will achieve commercial success or that the company will ever be profitable.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "mid-2027" liquidity estimate given the increased burn rate from Phase 3 enrollment.
- PROACT 1 Enrollment: Monitor patient enrollment rates and any potential delays in the Phase 3 trial that could impact the 2027 data readout.
- Equity Dilution: Review the terms of the Exchange Agreement and the 53% redeemable noncontrolling interest, which may lead to future dilution or cash settlements.
- Capital Raising: Assess the company's ability to raise additional capital if the current runway proves insufficient, considering market volatility.
- Regulatory Status: Confirm the continued RMAT (Regenerative Medicine Advanced Therapy) designation and any new FDA communications regarding the trial design.